EUVIMEDEUVIMED entdecken
Leserbrief

Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations

Kritika Subramanian, Joseph R Osborne

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1854.2-1855

DOI: 10.2967/jnumed.126.272700 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.09.2026. Verfasst von Kritika Subramanian und 1 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TO THE EDITOR: We read with great interest the study by Gogebakan et al. ([1][1]) regarding the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer from a U.S. perspective. The authors are to be commended for their methodology, including the

Zitieren

APA

Subramanian, K., & Osborne, J. R. (2026). Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations. Journal of Nuclear Medicine, 67(11), 1854.2-1855. https://doi.org/10.2967/jnumed.126.272700

Vancouver

Subramanian K, Osborne JR. Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations. Journal of Nuclear Medicine. 2026;67(11):1854.2-1855. doi:10.2967/jnumed.126.272700

BibTeX
@article{Subramanian2026,
  author = {Subramanian, Kritika and Osborne, Joseph R},
  title = {Cost-Effectiveness of 177 Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1854.2--1855},
  doi = {10.2967/jnumed.126.272700}
}
Kostenlos starten →